Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B
Richard Lemons,
Michael Wang,
Julie Curtin,
Lynda Mae Lepatan,
Christoph Male,
Flora Peyvandi,
Mario von Depka Prondzinski,
Rongrong Wang,
William McKeand,
Wilfried Seifert,
Johannes Oldenburg
Affiliations
Richard Lemons
Department of Pediatrics and Primary Children's Hospital, University of Utah, Salt Lake City, Utah, United States
Michael Wang
Hemophilia and Thrombosis Center, University of Colorado School of Medicine, Colorado, United States
Julie Curtin
The Children's Hospital at Westmead, New South Wales, Australia
Lynda Mae Lepatan
Department of Health Research and Pediatrics, Cebu Normal University—Vicente Sotto Memorial Medical Center College of Medicine, Cebu, Philippines
Christoph Male
Department of Paediatrics, Medical University of Vienna, Vienna, Austria
Flora Peyvandi
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
Mario von Depka Prondzinski
Werlhof Institute, Hannover, Germany
Rongrong Wang
CSL Behring, King of Prussia, Pennsylvania, United States
William McKeand
CSL Behring, King of Prussia, Pennsylvania, United States
Wilfried Seifert
CSL Behring, Marburg, Germany
Johannes Oldenburg
Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany
Introduction Recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) has been shown to be an effective, well-tolerated treatment for patients with severe hemophilia B who had previously received factor replacement therapy. This study investigated the safety and efficacy of rIX-FP in previously untreated patients (PUPs).
